EVerMed Inc.

Advancing Medicine
with Extracellular Vesicle Innovation.

EVイノベーションで、医療を前へ。

We develop next-generation therapeutics using the unique biological functions of extracellular vesicles (EVs), aiming for long-lasting and clinically meaningful treatments in respiratory medicine.

EVerMed’s Lead Pipeline EM-001 Adopted into AMED’s Pre-Designation Orphan Drug Support Program

EVerMed is pleased to announce that our lead pipeline candidate, EM-001, has been selected by the Japan Agency for Medical Research and Development (A...

News

About Us

“Being a pioneer
in innovative extracellular vesicle medicine”

Extracellular vesicles (EVs) serve as vital messengers in cell-to-cell communication, carrying a rich cargo of nucleic acids and proteins. Unlike conventional small molecules, antibodies, or synthetic DDS, EVs deliver a unique "multi-target" therapeutic effect through the synergy of these diverse molecules. At EVerMed, we believe in the transformative potential of EVs and are dedicated to pioneering their application as next-generation therapeutics.

Our Mission

“Being a pioneer in innovative extracellular vesicle medicine”
We develop transformative EV pipelines while building the platform to industrialize EV therapeutics.

Members

Led by globally recognized EV scientists and experienced biotech leaders, EVerMed bridges scientific excellence with strategic execution.

Partnerships

We seek pharmaceutical, biotech, academic, and strategic partners who share our vision to advance EV therapeutics and build the future of EV medicine.

EVs are

Extracellular vesicles (EVs) are nano-sized vesicles secreted by cells that play a pivotal role in intercellular communication. We recognize EVs as a next-generation therapeutic modality, focusing specifically on the following key characteristics:

Natural nanoparticles (40–150 nm) that deliver cargo to cells

Multifunctional mechanisms of action

Carry diverse biomolecules (miRNA, mRNA, proteins)

Enable co-delivery of multiple cargos

Pipeline

Our pipeline focuses on addressing significant unmet medical needs in respiratory diseases by targeting the fundamental mechanisms underlying disease progression.

Through both extracellular vesicle (EV)-based therapeutics and small-molecule approaches, we aim to modulate pathological processes such as cellular senescence, aberrant tissue remodeling, and fibrosis, thereby enabling both disease suppression and tissue regeneration.

News

We share updates on our research progress, scientific presentations, corporate announcements, and other key activities.
Stay informed about EVerMed’s latest developments and milestones here.

News

2026.04.01

EVerMed’s Lead Pipeline EM-001 Adopted into AMED’s Pre-Designation Orphan Drug Support Program

EVerMed is pleased to announce that our lead pipeline candidate, EM-001, has been selected by the Japan Agency for Medical Research and Development (AMED) for its “Support Program for Practical Application of Orphan Drugs Before Designation,” a par...